Literature DB >> 11302810

Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo.

J Mosquera1, P A Warn, J Morrissey, C B Moore, C Gil-Lamaignere, D W Denning.   

Abstract

We have attempted to validate in Aspergillus flavus the main in vitro methodologies that have been used to detect resistance in Aspergillus fumigatus. We developed a murine model with two A. flavus isolates, one that was apparently resistant in vitro to amphotericin B (AFL5) and another that was resistant to itraconazole (AFL8). No correlation was found for amphotericin B in AFL5, since the in vivo response was compatible with a susceptible isolate. Modification of the in vitro susceptibility test methodology for amphotericin B was unsuccessful. Although AFL8 was apparently resistant to itraconazole in vitro, it was found to be susceptible in vivo. Additional in vitro work has detected weaknesses in the in vitro susceptibility methodology validated for A. fumigatus when applied to A. flavus. The principal problems are that changes in the inoculum have a large effect on the MICs of itraconazole for some A. flavus strains and that a trailing end point and spore sediment often appear when an inoculum with a higher colony count is used. We propose a modified method using a final inoculum of 2.5 x 10(4) CFU per ml of RPMI 1640 medium with 2% glucose buffered to pH 7.0 in a microtiter format, incubated for 48 h with no growth end point. Validation of this methodology requires one or more itraconazole-resistant A. flavus isolates, which have yet to be identified.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302810      PMCID: PMC90488          DOI: 10.1128/AAC.45.5.1456-1462.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

2.  Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

Authors:  E M Johnson; K L Oakley; S A Radford; C B Moore; P Warn; D W Warnock; D W Denning
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

3.  Itraconazole resistance in Aspergillus fumigatus.

Authors:  D W Denning; K Venkateswarlu; K L Oakley; M J Anderson; N J Manning; D A Stevens; D W Warnock; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Experimental avian aspergillosis.

Authors:  J J Taylor; E J Burroughs
Journal:  Mycopathol Mycol Appl       Date:  1973-11-15

5.  The trailing end point phenotype in antifungal susceptibility testing is pH dependent.

Authors:  K A Marr; T R Rustad; J H Rex; T C White
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Inactivity of terbinafine in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; J Andrade; F Edwards; Y Niki; E Bernard; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

7.  Ketoconazole: a new imidazole antifungal agent has both prophylactic potential and therapeutic efficacy in keratomycosis of rabbits.

Authors:  E O Oji
Journal:  Int Ophthalmol       Date:  1982-11       Impact factor: 2.031

Review 8.  Invasive aspergillosis in patients with AIDS.

Authors:  S H Khoo; D W Denning
Journal:  Clin Infect Dis       Date:  1994-08       Impact factor: 9.079

9.  Experimental murine invasive pulmonary aspergillosis.

Authors:  D J Eisenstein; P W Biddinger; J C Rhodes
Journal:  Am J Clin Pathol       Date:  1990-04       Impact factor: 2.493

10.  Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.

Authors:  D W Denning; L Hall; M Jackson; S Hollis
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  17 in total

1.  Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Joseph Meletiadis; Rafal Al-Saigh; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides; Loukia Zerva
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.

Authors:  Elisabeth Maurer; Ulrike Binder; Manuela Sparber; Michaela Lackner; Rita Caramalho; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

Review 3.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

4.  Azole cross-resistance in Aspergillus fumigatus.

Authors:  J Mosquera; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 6.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

7.  Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Amel Aberkane; Eva Petrikkou; Emilia Mellado; Juan Luis Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Rafal Al-Saigh; Maria Siopi; Nikolaos Siafakas; Aristea Velegraki; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

9.  Conidial viability assay for rapid susceptibility testing of Aspergillus species.

Authors:  S Arunmozhi Balajee; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

10.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.